Analysts Anticipate Insulet Co. (PODD) Will Post Quarterly Sales of $125.25 Million
Brokerages predict that Insulet Co. (NASDAQ:PODD) will announce $125.25 million in sales for the current fiscal quarter, according to Zacks. Ten analysts have made estimates for Insulet’s earnings. The highest sales estimate is $127.49 million and the lowest is $124.20 million. Insulet reported sales of $103.58 million during the same quarter last year, which indicates a positive year-over-year growth rate of 20.9%. The firm is scheduled to report its next earnings report on Monday, February 26th.
On average, analysts expect that Insulet will report full year sales of $125.25 million for the current fiscal year, with estimates ranging from $447.00 million to $460.79 million. For the next year, analysts anticipate that the business will post sales of $557.17 million per share, with estimates ranging from $510.43 million to $588.51 million. Zacks’ sales calculations are an average based on a survey of sell-side analysts that that provide coverage for Insulet.
Insulet (NASDAQ:PODD) last released its quarterly earnings results on Thursday, November 2nd. The medical instruments supplier reported ($0.04) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.10) by $0.06. The firm had revenue of $121.80 million for the quarter, compared to the consensus estimate of $114.02 million. Insulet had a negative net margin of 6.66% and a negative return on equity of 43.85%. The firm’s quarterly revenue was up 28.4% on a year-over-year basis. During the same quarter in the previous year, the firm posted ($0.05) EPS.
A number of research analysts have issued reports on PODD shares. Zacks Investment Research lowered shares of Insulet from a “hold” rating to a “sell” rating in a research note on Tuesday. BidaskClub lowered shares of Insulet from a “buy” rating to a “hold” rating in a research note on Saturday, December 2nd. Barclays boosted their price target on shares of Insulet from $70.00 to $75.00 and gave the company an “overweight” rating in a report on Monday, November 20th. UBS Group upgraded shares of Insulet from a “market perform” rating to an “outperform” rating in a research note on Monday. Finally, Raymond James Financial raised shares of Insulet from a “market perform” rating to an “outperform” rating and set a $80.00 target price for the company in a research report on Monday. One equities research analyst has rated the stock with a sell rating, seven have issued a hold rating and twelve have assigned a buy rating to the stock. The company presently has an average rating of “Buy” and a consensus target price of $62.53.
In related news, Director James C. Mullen bought 2,500 shares of the company’s stock in a transaction on Monday, November 13th. The shares were purchased at an average cost of $67.45 per share, for a total transaction of $168,625.00. The purchase was disclosed in a document filed with the SEC, which is accessible through the SEC website. Company insiders own 2.60% of the company’s stock.
A number of institutional investors and hedge funds have recently modified their holdings of the stock. GSA Capital Partners LLP acquired a new position in Insulet during the third quarter worth $1,414,000. California Public Employees Retirement System boosted its position in Insulet by 9.2% during the third quarter. California Public Employees Retirement System now owns 71,744 shares of the medical instruments supplier’s stock worth $3,952,000 after purchasing an additional 6,044 shares during the period. Janney Montgomery Scott LLC bought a new position in Insulet during the third quarter worth $3,229,000. Cubist Systematic Strategies LLC bought a new position in Insulet during the third quarter worth $406,000. Finally, Point72 Asset Management L.P. bought a new position in Insulet during the third quarter worth $33,373,000.
Shares of Insulet (NASDAQ PODD) traded up $0.75 during trading hours on Thursday, hitting $75.83. 965,800 shares of the company were exchanged, compared to its average volume of 780,943. The company has a current ratio of 4.88, a quick ratio of 4.42 and a debt-to-equity ratio of 4.65. Insulet has a twelve month low of $38.43 and a twelve month high of $78.65. The company has a market cap of $4,410.00, a P/E ratio of -151.66 and a beta of 1.58.
Insulet Company Profile
Insulet Corporation is engaged in the development, manufacturing and sale of the OmniPod Insulin Management System (the OmniPod System), an insulin delivery system for people with insulin-dependent diabetes. The Omnipod System features a self-adhesive disposable tubeless Omnipod device, which is worn on the body for approximately three days at a time and its wireless companion, the handheld Personal Diabetes Manager (PDM).
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Insulet Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Insulet and related companies with MarketBeat.com's FREE daily email newsletter.